Antibody acting against tumour cell

Antibody acting against tumour cell

C029/0093 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 53.6MB

Downloadable file size: 818.9KB

Price image Pricing

Please login to use the price calculator


Credit: ALFRED PASIEKA/SCIENCE PHOTO LIBRARY

Caption: Computer artwork of monoclonal antibodies, bi-specific T-cell engagers (BiTEs), acting against tumour cells. Blinatumomab (trade name) specifically targets the CD19 antigen present on B cells. Blinatumomab enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor. The drug works by linking these two cell types and activating the T cell to exert cytotoxic activity on the target cell.Blinatumomab is used as a second-line treatment against acute lymphoblastic leukemia. The image shows a cancer cell (red, down left) and an immune cell (blue, upper right) connected by the Blinatumomab bi-specific antibody.

Release details: Model release not required. Property release not required.

Keywords: activating, activity, acute, adult, antibodies, antibody, antigen, artwork, bi-specific, bites, cancer, cd19, cd3, cell, cells. blinatumomab, combines, cut out, cut outs, cut-out, cut-outs, cutout, cutouts, cytotoxic, drug, illustration, leukemia, linking, lymphoblastic, malignant, molecule, monoclonal, patients, pediatric, potential, receptor, second-line, t cells, t-cell engagers, target, therapeutic, treatment, tumor, tumour, two binding sites

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.